Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Crizanlizumab |
Synonyms | |
Therapy Description |
Crizanlizumab is an antibody that inhibits P-selectin (SELP) (Cancer Res (2024) 84 (6_Supplement): 4031). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Crizanlizumab | Adakveo|SEG101|SEG-101|SEG 101 | Crizanlizumab is an antibody that inhibits P-selectin (SELP) (Cancer Res (2024) 84 (6_Supplement): 4031). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05909618 | Phase II | Crizanlizumab + Nivolumab Crizanlizumab | Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases (14) | Recruiting | ISR | 0 |